Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations

被引：3

作者：

Pelster, M. S. ^{[1
]}

Yaeger, R. ^{[2
]}

Klempner, S. J. ^{[3
]}

Ou, S-H. I. ^{[4
]}

Spira, A. I. ^{[5
,6
]}

Janne, P. A. ^{[7
]}

Uboha, N. V. ^{[8
]}

Gaffar, Y. A. ^{[9
]}

Newman, G. ^{[10
]}

Paweletz, C. P. ^{[11
]}

Heavey, G. A. ^{[12
]}

Alejandro, L. ^{[13
]}

Kheoh, T. ^{[14
]}

Anderes, K. ^{[15
]}

Torossian, H. Der ^{[16
]}

Christensen, J. G. ^{[17
]}

Weiss, J. ^{[18
]}

机构：

[1] Sarah Cannon Res Inst, Gastrointestinal Res, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[3] Massachusetts Gen Canc Ctr, Dept Med, Boston, MA USA

[4] UCI Hlth Chao Family Comprehens Canc Ctr, Dept Med, Orange, CA USA

[5] Virginia Canc Specialist, Res Inst, Fairfax, VA USA

[6] US Oncol Res, The Woodlands, TX USA

[7] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

[8] Univ Wisconsin, Med, Madison, TX USA

[9] Maryland Oncol Hematol, Med Oncol, Columbia, MD 8 USA

[10] Ridley Tree Canc Ctr, Clin Res, Santa Barbara, CA USA

[11] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[12] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA USA

[13] Mirati Therapeut Inc, Med Affairs, San Diego, CA USA

[14] Mirati Therapeut Inc, Biometr, San Diego, CA USA

[15] Mirati Therapeut Inc, Translat Med & Compan Diagnost, San Diego, CA USA

[16] Mirati Therapeut Inc, Clin Dev, San Diego, CA USA

[17] Mirati Therapeut Inc, San Diego, CA USA

[18] Univ N Carolina, Lineberger Comprehens Canc Ctr, Oncol, Chapel Hill, NC USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1740

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

549O

引用

页码：S410 / S410

页数：1

共 50 条

[41] KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation
Tabernero, J.
Bendell, J.
Corcoran, R.
Kopetz, S.
Lee, J.
Davis, M.
Christensen, J.
Chi, A.
Kheoh, T.
Yaeger, R.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S121 - S121
[42] A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
El Saadany, Tamer
Lupatsch, Judith E.
Mark, Michael
Barbier, Michaela
Mehra, Tarun
Schwenkglenks, Matthias
von Moos, Roger
[J]. SWISS MEDICAL WEEKLY, 2025, 155
[43] Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study
Xu, R-H.
Xu, Y.
Yan, D.
Munster, P.
Ruan, D.
Deng, Y.
Pan, H.
Underhill, C. R.
Richardson, G.
Nordman, I.
Lee, K-W.
Wei, S.
Li, X.
Shan, J.
Han, G.
Henderson, S.
Xie, X.
Xiang, Z.
Shi, Z.
Zhang, L.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S410 - S411
[44] WEE1 inhibition enhances anti-tumor activity of sotorasib in KRASG12C-mutated non-small cell lung cancer in preclinical models
Yamamoto, Gaku
Tanaka, Kosuke
Kamata, Ryo
Yamauchi, Toyohiro
Liu, Jie
Ohashi, Akihiro
Kobayashi, Susumu S.
[J]. CANCER SCIENCE, 2023, 114 : 1043 - 1043
[45] Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers.
Salem, Mohamed E.
El-Refai, Sherif
Sha, Wei
Grothey, Axel
Puccini, Alberto
George, Thomas J.
Hwang, Jimmy J.
Musselwhite, Laura W.
King, David
Kadakia, Kunal C.
Raghavan, Derek
Van Cutsem, Eric
Tabernero, Josep
Tie, Jeanne
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[46] Divarasib plus cetuximab in KRASG12C-positive colorectal cancer: a phase 1b trial
Desai, Jayesh
Alonso, Guzman
Kim, Se Hyun
Cervantes, Andres
Karasic, Thomas
Medina, Laura
Shacham-Shmueli, Einat
Cosman, Rasha
Falcon, Alejandro
Gore, Eelke
Guren, Tormod
Massarelli, Erminia
Miller, Wilson H., Jr.
Paz-Ares, Luis
Prenen, Hans
Amatu, Alessio
Cremolini, Chiara
Kim, Tae Won
Moreno, Victor
Ou, Sai-Hong, I
Passardi, Alessandro
Sacher, Adrian
Santoro, Armando
Stec, Rafal
Ulahannan, Susanna
Arbour, Kathryn
Lorusso, Patricia
Luo, Jia
Patel, Manish R.
Choi, Yoonha
Shi, Zhen
Mandlekar, Sandhya
Lin, Mark T.
Royer-Joo, Stephanie
Chang, Julie
Jun, Tomi
Dharia, Neekesh, V
Schutzman, Jennifer L.
Han, Sae-Won
[J]. NATURE MEDICINE, 2024, 30 (01) : 271 - +
[47] Analysis of Genetic Alterations in Colorectal Cancer (CRC) Patients in South Indian Population
Younis, Mohd
Arun, Meyyazhagan
Iqbal, Javaid
Kumar, Mithun
Arun, Sundaramoorthy
Cacabelos, Ramon
Sasikala, Keshavarao
Anand, Vijaya
[J]. INTERNATIONAL JOURNAL OF HUMAN GENETICS, 2018, 18 (03) : 210 - 218
[48] Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort
Masuishi, T.
Strickler, J. H.
Machiels, J-P.
Hong, D. S.
Greil, R.
Chan, E.
Hippenmeyer, J.
Saportas, Y.
Cardona, P.
Xia, C.
Kuboki, Y.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1505 - S1505
[49] Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer
Thein, Kyaw Z.
Biter, Amadeo B.
Banks, Kimberly C.
Duda, Andrew W.
Saam, Jennifer
Roszik, Jason
Janku, Filip
Skoulidis, Ferdinandos
Heymach, John V.
Kopetz, Scott
Meric-Bernstam, Funda
Hong, David S.
[J]. JCO PRECISION ONCOLOGY, 2022, 6
[50] Genomic alterations in circulating tumor DNA (ctDNA) and response to telisotuzumab adizutecan (ABBV-400) treatment in patients (pts) with colorectal cancer (CRC).
Cecchini, Michael
Sharma, Manish R.
Kuboki, Yasutoshi
Perets, Ruth
Cohen, Jonathan
Raimbourg, Judith
Nakajima, Takako Eguchi
Cruz-Correa, Marcia
Ghiringhelli, Francois
Raghav, Kanwal Pratap Singh
Vasilopoulos, Athanasios
Luo, Xizhi
Aristide, Martha Raluca Neagu
Thiele, Gladys Morrison
Hunter, Zoe
Burns, Michael Charles
Roberts-Rapp, Lisa
Strickler, John H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 258 - 258

← 1 2 3 4 5 →